Irbesartan/Hydrochlorothiazide Teva (Hydrochlorothiazide, Irbesartan)

Irbesartan selectively blocks the AT1 receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels and reduced fluid retention, contributing to lower blood pressure when combined with the diuretic effect of hydrochlorothiazide.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure goals, renal function, and other medical factors. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the regimen.

Safety in pregnancy and lactation has not been established. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and it is generally avoided unless no suitable alternatives exist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with monotherapy, the fixed‑dose combination offers dual mechanisms—angiotensin II blockade and diuresis—providing more consistent blood‑pressure control. It may reduce pill burden versus separate agents, but clinicians consider individual patient profiles, tolerability, and potential drug interactions when selecting therapy.

Store the tablets at or below 25 °C in a dry place. Keep them in the original container, protect from moisture and direct sunlight, and ensure they are out of reach of children.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, electrolyte imbalances (especially low potassium), acute kidney injury, hyperkalemia, and rare cases of angioedema. Patients should report sudden dizziness, swelling of the face or throat, or marked changes in urine output to their healthcare provider promptly.

The combination should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in severe renal impairment, anuria, and in patients with severe hepatic disease where safety has not been established.